Ifm_05-may 2022 May 2026

Early versus Late Discontinuation of Maintenance Therapy in ... - MDPI

Lenalidomide was the primary drug used for maintenance in this study. Key Findings: IFM_05-May 2022

Due to the risk of secondary cancers identified in the IFM-05 trial, long-term monitoring for new symptoms or blood changes is standard practice for those on this regimen. Early versus Late Discontinuation of Maintenance Therapy in

Patients are encouraged to discuss the balance between disease control and the toxic long-term effects of maintenance drugs with their oncology team. IFM_05-May 2022